THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS | Publicación